Efficacy and tolerability of docetaxel chemotherapy in 'real-world' patients with metastatic hormone-sensitive prostate cancer (mHSPC)

被引：0
|
作者：
Maw, May Tun Hla [1 ]
Malik, Laeeq [1 ]
机构：
[1] Canberra Hosp, Dept Med Oncol, Garran, ACT, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
206
引用
收藏
页码：127 / 127
页数：1
相关论文
共 50 条
  • [21] Comparison of outcomes with docetaxel or ARPI combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) by volume of disease
    Schoen, Martin W.
    Etzioni, Ruth Douglas
    Luo, Suhong
    Candelieri, Danielle
    Fedele, Nicholas
    Baxi, Priya
    Pickett, Carley
    Riekhof, Forest
    Ingram, Kara
    Karunanandaa, Krishny
    Govindan, Srinivas
    Cheranda, Nina
    Knoche, Eric Marshall
    Montgomery, Robert Bruce
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study
    Kai Ozaki
    Shingo Hatakeyama
    Shintaro Narita
    Kenichi Hata
    Takafumi Yanagisawa
    Toshikazu Tanaka
    Kyo Togashi
    Tomoko Hamaya
    Teppei Okamoto
    Hayato Yamamoto
    Takahiro Yoneyama
    Yasuhiro Hashimoto
    Takahiro Kimura
    Tomonori Habuchi
    Chikara Ohyama
    World Journal of Urology, 2023, 41 : 67 - 75
  • [23] ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC).
    Smith, Matthew Raymond
    Saad, Fred
    Hussain, Maha
    Sternberg, Cora N.
    Fizazi, Karim
    Yamada, Karin Sayuri
    Kappeler, Christian
    Kuss, Iris
    Tombal, Bertrand F.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [24] Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study
    Ozaki, Kai
    Hatakeyama, Shingo
    Narita, Shintaro
    Hata, Kenichi
    Yanagisawa, Takafumi
    Tanaka, Toshikazu
    Togashi, Kyo
    Hamaya, Tomoko
    Okamoto, Teppei
    Yamamoto, Hayato
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Kimura, Takahiro
    Habuchi, Tomonori
    Ohyama, Chikara
    WORLD JOURNAL OF UROLOGY, 2023, 41 (01) : 67 - 75
  • [25] REAL-WORLD TREATMENT PATTERNS IN THE METASTATIC HORMONE-SENSITIVE PROSTATE CANCER SETTING ACROSS EUROPE
    Castro, E.
    Orji, C.
    Ribbands, A.
    Butcher, J.
    Walley, M.
    Li, W.
    Ghate, S.
    VALUE IN HEALTH, 2024, 27 (06) : S231 - S232
  • [26] Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm
    Weiner, Adam B.
    Nettey, Oluwarotimi S.
    Morgans, Alicia K.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (09)
  • [27] IDENTIFYING AND CHARACTERIZING METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) POPULATION IN FINLAND
    Ruotsalainen, J.
    Korhonen, M. J.
    Purmonen, T.
    Joutseno, J.
    Saavuori, N.
    VALUE IN HEALTH, 2023, 26 (12) : S535 - S535
  • [28] Docetaxel Improves Survival in Metastatic Hormone-Sensitive Prostate Cancer
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (09) : 549 - 549
  • [29] Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?
    Kartolo, Adi
    Tannock, Ian F.
    Badillo, Francisco E. Vera
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (31) : 3573 - +
  • [30] Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
    Talwar, Harkirat Singh
    INDIAN JOURNAL OF UROLOGY, 2021, 37 (03) : 288 - 290
12345